| First Author | Mann SN | Year | 2020 |
| Journal | Elife | Volume | 9 |
| PubMed ID | 33289482 | Mgi Jnum | J:300696 |
| Mgi Id | MGI:6490412 | Doi | 10.7554/eLife.59616 |
| Citation | Mann SN, et al. (2020) Health benefits attributed to 17alpha-estradiol, a lifespan-extending compound, are mediated through estrogen receptor alpha. Elife 9:e59616 |
| abstractText | Metabolic dysfunction underlies several chronic diseases, many of which are exacerbated by obesity. Dietary interventions can reverse metabolic declines and slow aging, although compliance issues remain paramount. 17alpha-estradiol treatment improves metabolic parameters and slows aging in male mice. The mechanisms by which 17alpha-estradiol elicits these benefits remain unresolved. Herein, we show that 17alpha-estradiol elicits similar genomic binding and transcriptional activation through estrogen receptor alpha (ERalpha) to that of 17beta-estradiol. In addition, we show that the ablation of ERalpha completely attenuates the beneficial metabolic effects of 17alpha-E2 in male mice. Our findings suggest that 17alpha-E2 may act through the liver and hypothalamus to improve metabolic parameters in male mice. Lastly, we also determined that 17alpha-E2 improves metabolic parameters in male rats, thereby proving that the beneficial effects of 17alpha-E2 are not limited to mice. Collectively, these studies suggest ERalpha may be a drug target for mitigating chronic diseases in male mammals. |
